Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Retraction Note: A significant causal association between C-reactive protein levels and schizophrenia

The Original Article was published on 19 May 2016

Correction to: Scientific Reports 6: Article number: 26105; published online: 19 May 2016; updated: 21 February 2018

The authors are retracting this Article. The Article comprises three parts: a case-control study; a meta-analysis of case-control studies; and Mendelian randomization (MR) analyses (two datasets; a Japanese dataset and a public genome-wide association study [GWAS]-pooled dataset). In the MR analysis using the public dataset, the authors mistook effect alleles, resulting in incorrect results (Figure 3) and conclusion.

Our updated MR results are as follows: odds ratio (OR)scz/crp 0.87 (95% CI 0.76–1.00, p = 0.046) using rs2794520; 0.83 (95% CI 0.72–0.96, p = 0.014) using rs1183910; 0.85 (95% CI 0.77–0.94, p = 0.0017) across these two single nucleotide polymorphisms (SNPs); and 0.89 (95% CI 0.82–0.97, p = 0.006) using 15 C-reactive protein (CRP)-associated SNPs, which reached genome-wide significance in a meta-analysis of GWAS, respectively. These updated results of the MR analysis using the limited number of SNPs indicate a protective causal association between elevated CRP levels and schizophrenia risk. Therefore, the hypothesis in the conclusion of the Article—that medications which reduce CRP levels can be used in schizophrenia—is not supported.

All authors recognize these miscalculations in the original MR analysis and have agreed to the retraction of this Article.


Additional information

The online version of the original article can be found at

Rights and permissions

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Inoshita, M., Numata, S., Tajima, A. et al. Retraction Note: A significant causal association between C-reactive protein levels and schizophrenia. Sci Rep 8, 46947 (2018).

Download citation

  • Published:

  • DOI:

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing